Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 653 trials

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.

Pulmonary Alveolar Proteinosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsPulmonology

Cancer Imaging: [18F]AlF-FAPI-74 PET/CT

We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.

Pancreatic CancerEsophagogastric AdenocarcinomaGastric Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

Haemophilia A1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOrthopedics and Traumatology

Pain Management After Colorectal Surgery: Continuous Wound Infusion Study

We are investigating whether continuous infusion of local pain relief helps patients recover better after minimally invasive colorectal surgery. The study compares this method to a placebo to see its effects on pain and recovery time.

Recovery After Colorectal Surgery1-2 yearsConfirmation phase (III)Standard MedicinesGastroenterologyInternal MedicineOtolaryngology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Burn Treatment in Children: New Skin Graft Study

We are testing a new skin graft made from the child's own cells for treating severe burns in children. The goal is to see if it works better and is safer than the standard skin graft method.

Children with Severe Burns1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Cataract Surgery: Preoperative NSAIDs Study

We are comparing how different medication regimens affect inflammation after cataract surgery. This study aims to find the best approach to improve recovery for patients.

Cataract1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOphthalmology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

RCS-21: Safety Study in Healthy Volunteers

We are testing the safety and tolerability of the compound RCS-21 in healthy individuals. This study will help us understand how the body absorbs and eliminates this drug.

Healthy Participants1-2 yearsSafety phase (I)Pulmonology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Tumor Treatment: ABX-001 Immunotherapy

We are testing a new immunotherapy, ABX-001, alone and with pembrolizumab for patients with tumors that have been treated before. The goal is to see if this combination can improve treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Cochlear Implant Surgery: Testing VSF1.01 Treatment

We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.

Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboOtolaryngology